2024
Long-Term Maintenance of Optimal Treatment Targets for Skin and Itch Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Phase 3 Measure Up 1 and 2 Studies
Issa N, Chovatiya R, Talia J, Torres T, Eyerich K, Calimlim B, Yang Y, Pechonkina A, Moreira A, Grada A, Bunick C. Long-Term Maintenance of Optimal Treatment Targets for Skin and Itch Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Phase 3 Measure Up 1 and 2 Studies. SKIN The Journal Of Cutaneous Medicine 2024, 8: s449. DOI: 10.25251/skin.8.supp.449.Peer-Reviewed Original ResearchAtopic dermatitisModerate-to-severe atopic dermatitisLong-term disease controlClinically meaningful responseProlonged systemic therapyProportion of patientsUpadacitinib treatmentOptimal treatment targetsSystemic therapyOptimal treatmentMeaningful responseJAK inhibitorsInterim analysisPatientsUpadacitinibLong-term maintenanceTreatment targetItchingOptimal outcomesWeeksDermatitisDisease controlOutcomesSkinPhase 3640 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis
Bunick C, Bhatia N, Del Rosso J, Draelos Z, Eichenfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. 640 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis. British Journal Of Dermatology 2024, 191: ljae266.021. DOI: 10.1093/bjd/ljae266.021.Peer-Reviewed Original ResearchPhase 3 trialLocal tolerancePatient treatment adherenceAdverse eventsAtopic dermatitisSeborrheic dermatitisPenetration enhancersRoflumilast-treated patientsRate of adverse eventsTreatment adherencePatient-rated assessmentsApplication siteTopical medicationsIntertriginous areasRoflumilast creamDay 1Water-based creamRoflumilastInvestigational productPatientsInvestigator-PsoriasisDermatitisPrescription productsTrialsRapid Remission of Plaque Psoriasis With Bimekizumab Treatment.
Abdin R, Gharib R, Bunick C, Issa N. Rapid Remission of Plaque Psoriasis With Bimekizumab Treatment. Journal Of Drugs In Dermatology 2024, 23: 694-696. PMID: 39093648, DOI: 10.36849/jdd.8381.Peer-Reviewed Original ResearchConceptsPlaque psoriasisIL-17AIL-17FAnti-IL-17 biologicsSafety of bimekizumabPathogenesis of psoriasisMonoclonal immunoglobulin G1Psoriasis patientsBimekizumabTreatment optionsClinical trialsPsoriasisMedical literatureClearance timeImmunoglobulin G1Rapidity of responseTreatmentPatientsEfficacyClearancePlaqueBrodalumabCytokinesPathogenesisReceptors504 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis
Bunick C, Bhatia N, Del Rosso J, Draelos Z, Eichenfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. 504 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis. British Journal Of Dermatology 2024, 190: ii9-ii10. DOI: 10.1093/bjd/ljad498.012.Peer-Reviewed Original ResearchPhase 3 trialLocal tolerancePatient treatment adherenceAdverse eventsPenetration enhancersRoflumilast-treated patientsRate of adverse eventsTreatment adherencePatient-rated assessmentsApplication siteTopical medicationsIntertriginous areasAtopic dermatitisRoflumilast creamDay 1Seborrheic dermatitisWater-based creamRoflumilastInvestigational productPatientsInvestigator-PsoriasisPrescription productsTrialsClinicInvestigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis
Bunick C, Bhatia N, Del Rosso J, Draelos Z, Eichenfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Stein Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s309. DOI: 10.25251/skin.8.supp.309.Peer-Reviewed Original ResearchPhase 3 trialLocal toleranceAdverse eventsPatient treatment adherencePatients discontinued due to adverse eventsAtopic dermatitisSeborrheic dermatitisPenetration enhancersRoflumilast-treated patientsRate of adverse eventsTreatment adherencePatient-rated assessmentsApplication siteTopical medicationsIntertriginous areasRoflumilast creamDay 1RoflumilastWater-based creamInvestigator-Investigational productPatientsPsoriasisDermatitisPrescription products
2023
Congenital Ichthyosis: A Practical Clinical Guide on Current Treatments and Future Perspectives
Lilly E, Bunick C. Congenital Ichthyosis: A Practical Clinical Guide on Current Treatments and Future Perspectives. Clinical Cosmetic And Investigational Dermatology 2023, 16: 2473-2479. PMID: 37719935, PMCID: PMC10503504, DOI: 10.2147/ccid.s388608.Peer-Reviewed Original ResearchDisease-specific recommendationsPractical clinical guideEye complicationsClinical reviewLongitudinal careGrowth restrictionClinical guideCurrent treatmentDermatological therapyHereditary disorderCongenital ichthyosesOrphan conditionAffected individualsComplicationsTreatmentThermodysregulationPatientsTherapyInfectionKeratinizationCare42262 Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)
Silverberg J, Deleuran M, Gold L, Bunick C, Hijnen D, Calimlim B, Teixeira H, Platt A, Grada A, Hu X, Gooderham M. 42262 Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up). Journal Of The American Academy Of Dermatology 2023, 89: ab90. DOI: 10.1016/j.jaad.2023.07.365.Peer-Reviewed Original ResearchCircadian Oscillations of Minimal Erythema Dose (MED) are Also Influenced by Diet in Patients with Psoriasis: A Chronomedical Study
Damiani G, Pacifico A, Scoditti E, di Gregorio S, Del Fabbro M, Cozzolino C, Buja A, Mercuri S, Bianchi V, Grada A, Garbarino S, Bunick C. Circadian Oscillations of Minimal Erythema Dose (MED) are Also Influenced by Diet in Patients with Psoriasis: A Chronomedical Study. Dermatology And Therapy 2023, 13: 2229-2246. PMID: 37573289, PMCID: PMC10539244, DOI: 10.1007/s13555-023-00987-z.Peer-Reviewed Original ResearchMinimal erythema dosePsoriatic patientsPsO patientsCohort studyNB-UVBErythema doseNB-UVB therapyLow minimal erythema doseDifferent dietsUVB phototherapyOngoing therapyDiet modulationMedical recordsHealthy controlsRamadan fastingPatientsHealthy individualsDietSignificant differencesPsoriasisMED valuesTherapyCircadian rhythmDosePhototherapyTrends in Oral Antibiotic Use for Acne Treatment: A Retrospective, Population-Based Study in the United States, 2014 to 2016.
Grada A, Armstrong A, Bunick C, Salem R, Feldman S. Trends in Oral Antibiotic Use for Acne Treatment: A Retrospective, Population-Based Study in the United States, 2014 to 2016. Journal Of Drugs In Dermatology 2023, 22: 265-270. PMID: 36877883, DOI: 10.36849/jdd.7345.Peer-Reviewed Original ResearchConceptsOral antibiotic useOral antibioticsAntibiotic useAntibiotic treatmentAcne treatmentHealth care claims dataOral antibiotic treatmentShort study durationIBM MarketScanPrimary outcomeGuideline recommendationsRetrospective studyAcne vulgarisRetrospective analysisClaims dataJ DrugsPatientsStudy durationAmerican AcademyTherapeutic classesSeparate occasionsDay gapMonthsAntibiotic resistanceAntibiotics
2022
Inguinal patch in mpox (monkeypox) virus infection and eccrine syringometaplasia: report of two cases with in situ hybridization and electron microscopy findings
Roy S, Sarhan J, Liu X, Murphy M, Bunick C, Choate K, Damsky W, McNiff J. Inguinal patch in mpox (monkeypox) virus infection and eccrine syringometaplasia: report of two cases with in situ hybridization and electron microscopy findings. British Journal Of Dermatology 2022, 188: 574-576. PMID: 36763786, DOI: 10.1093/bjd/ljac146.Peer-Reviewed Original ResearchConceptsVirus infectionUnusual clinical findingsElectron microscopy findingsEccrine epitheliumSquamous syringometaplasiaClinical findingsSitu hybridizationEccrine ductsMicroscopy findingsSyringometaplasiaUltrastructural characteristicsInfectionViral mRNAsFindingsPatientsHistopathologicalDiseaseEpitheliumTruncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management
Daniele S, Kim S, Grada A, Moore A, Suozzi K, Bunick C. Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management. American Journal Of Clinical Dermatology 2022, 24: 199-223. PMID: 36539678, DOI: 10.1007/s40257-022-00746-4.Peer-Reviewed Original ResearchConceptsTruncal acne vulgarisAcne vulgarisTruncal acneHalf of patientsFacial acne vulgarisSignificant psychosocial burdenAvailable treatment optionsCommon skin disorderTreatment guidelinesPsychosocial burdenTreatment optionsTruncal involvementPatient managementFacial lesionsClinical problemSkin disordersUpper armCosmetic approachSebaceous glandsCurrent MedicalSkin areasPatientsAcneFocused reviewFurther investigationStenotrophomonas maltophilia, a Pathogen of Increasing Relevance to Dermatologists: A Case Report and Review of the Literature
Belzer A, Weiss E, Etaee F, Bunick CG, Damsky W, Nelson CA. Stenotrophomonas maltophilia, a Pathogen of Increasing Relevance to Dermatologists: A Case Report and Review of the Literature. Antibiotics 2022, 11: 1398. PMID: 36290055, PMCID: PMC9598652, DOI: 10.3390/antibiotics11101398.Peer-Reviewed Original ResearchSoft tissue infectionsUrinary tract infectionChronic lymphocytic leukemiaGram-negative bacilliTract infectionsImmunocompetent populationTissue infectionsHigh morbidityAplastic anemiaCase reportLymphocytic leukemiaInfectionBacteremiaCurrent standardStenotrophomonas maltophiliaDermatologistsLimited optionsMorbidityPneumoniaPatientsAnemiaTherapyLeukemiaMortalityPrevalence
2021
Genotype‒Structurotype‒Phenotype Correlations in Patients with Pachyonychia Congenita
Wu TT, Eldirany SA, Bunick CG, Teng JMC. Genotype‒Structurotype‒Phenotype Correlations in Patients with Pachyonychia Congenita. Journal Of Investigative Dermatology 2021, 141: 2876-2884.e4. PMID: 34116063, PMCID: PMC8922998, DOI: 10.1016/j.jid.2021.03.035.Peer-Reviewed Original ResearchConceptsPachyonychia congenitaInternational PC Research RegistryPainful palmoplantar keratodermaPhenotype correlationNatal teethNail involvementClinical manifestationsKeratin subtypesFollicular hyperkeratosisResearch RegistryOral leukokeratosisPC pathogenesisNail dystrophyPathologic alterationsCutaneous cystsDisease pathogenesisHotspot missense mutationsPatientsClinical phenotypeGreater impairmentGenetic testingHigh-frequency mutationsTherapeutic developmentPalmoplantar keratodermaGenetic disorders